Literature DB >> 16012875

Scleroderma associated with ANCA-associated vasculitis.

Young Hee Rho1, Seong Jae Choi, Young Ho Lee, Jong Dae Ji, Gwan Gyu Song.   

Abstract

Scleroderma and ANCA-associated vasculitides (AAV), such as microscopic polyangiitis, are distinct disease entities, but are rarely known to coexist with each other. We have reported on two cases of scleroderma patients for the first time in Korea, and these patients were initially known to have only limited type scleroderma with pulmonary fibrosis, but eventually they were found to be ANCA-positive with the associated clinical features of vasculitis. Both were treated with high-dose steroids and cyclophosphamide and remitted without major sequelae. When scleroderma patients exhibit atypical features such as normotensive renal failure with signs of active inflammation, the possibility of AAV should always be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012875     DOI: 10.1007/s00296-005-0003-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  Antineutrophil cytoplasmic antibodies a "Red Flag" in patients with systemic sclerosis.

Authors:  Sylvia Casari; Mansel Haeney; Sue Farrand; Ariane Herrick
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Systemic sclerosis and antineutrophil cytoplasmic autoantibody-associated renal failure.

Authors:  A Katrib; A Sturgess; J V Bertouch
Journal:  Rheumatol Int       Date:  1999       Impact factor: 2.631

3.  Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies -- related scleroderma renal crisis treated with double-filtration plasmapheresis.

Authors:  A Omote; M Muramatsu; Y Sugimoto; S Hosono; R Murakami; H Tanaka; Y Watanabe; H Sano; K Kato
Journal:  Intern Med       Date:  1997-07       Impact factor: 1.271

4.  Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature.

Authors:  Paolo Caramaschi; Domenico Biasi; Elisabetta Tonolli; Antonio Carletto; Lisa Maria Bambara
Journal:  Joint Bone Spine       Date:  2002-03       Impact factor: 4.929

5.  Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis.

Authors:  Amelia Ruffatti; Renato Alberto Sinico; Antonella Radice; Elena Ossi; Franco Cozzi; Marta Tonello; Panagiotis Grypiotis; Silvano Todesco
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

6.  The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase.

Authors:  P B Gaudin; F B Askin; R J Falk; J C Jennette
Journal:  Am J Clin Pathol       Date:  1995-07       Impact factor: 2.493

7.  Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.

Authors:  Dhanita Khanna; Amita Aggarwal; Darshan S Bhakuni; Rajeshwar Dayal; Ramnath Misra
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

8.  Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Sakae Homma; Hiroshi Matsushita; Koichiro Nakata
Journal:  Respirology       Date:  2004-06       Impact factor: 6.424

Review 9.  Microscopic polyangiitis: clinical aspects and treatment.

Authors:  F Lhote; P Cohen; T Généreau; M Gayraud; L Guillevin
Journal:  Ann Med Interne (Paris)       Date:  1996

10.  Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis.

Authors:  H Endo; T Hosono; H Kondo
Journal:  J Rheumatol       Date:  1994-05       Impact factor: 4.666

View more
  2 in total

1.  Microscopic polyangiitis in systemic sclerosis.

Authors:  Hiroshi Hashimoto
Journal:  Int J Rheumatol       Date:  2010-08-09

2.  Antineutrophil cytoplasmic antibody-positive digital necrosis in a patient with limited systemic sclerosis.

Authors:  Maida Wong; Veena K Ranganath; Philip J Clements
Journal:  J Rheumatol       Date:  2010-01       Impact factor: 4.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.